Protagonist Therapeutics Inc annual net income for fiscal TTM was $84 million, compared with -$130 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $84M | ($130M) | $275M | ($79M) | ($123M) | ($126M) | ($66M) | ($77M) | ($39M) | ($37M) | ($37M) | ($15M) | ($11M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | $163M | $4M | ($44M) | ($39M) | ($35M) | ($12M) | $132M | ($33M) | ($31M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PTGX metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All PTGX financial statements → Interactive PTGX charts →
About TickerBase · Data methodology & sources · Privacy · Terms